A recent study exploring abatacept’s efficacy in post-kidney transplant FSGS patients who developed FSGS after transplantation and failed conventional therapy revealed that responders to abatacept were B7-1 positive. Here, CD80 is linked to focal segmental glomerulosclerosis.